SWP
VRTX icon

Sagespring Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Sagespring Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Sell
3,382
-252
-7% -$112K 0.03% 239
2026
Q1 		$1.62M Buy
3,634
+47
+1% +$21.9K 0.03% 223
2025
Q4 		$1.63M Buy
3,587
+657
+22% +$283K 0.03% 220
2025
Q3 		$1.15M Sell
2,930
-255
-8% -$107K 0.02% 277
2025
Q2 		$1.42M Sell
3,185
-45
-1% -$20.7K 0.03% 217
2025
Q1 		$1.57M Buy
3,230
+934
+41% +$435K 0.04% 182
2024
Q4 		$925K Buy
+2,296
New +$1.06M 0.02% 233

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sagespring Wealth Partners's VRTX Position: Q2 2026 in Review

Sagespring Wealth Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 6.9% in Q2 2026, selling an estimated $112K and leaving 3,382 shares worth $1.68M. The position accounts for 0.03% of the portfolio, ranked #239.

Sagespring Wealth Partners first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sagespring Wealth Partners held 3,382 shares of Vertex Pharmaceuticals worth $1.68M as of Q2 2026.
  • Sagespring Wealth Partners sold 252 Vertex Pharmaceuticals shares in Q2 2026, an estimated $112K.
  • Vertex Pharmaceuticals made up 0.03% of Sagespring Wealth Partners's portfolio in Q2 2026, its #239 holding.
  • Sagespring Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sagespring Wealth Partners's 13F filing for Q2 2026, filed 3 Aug 2026.